Trial reportClinical endocrinology2026
Puberty-Promoting Treatment and Psychosocial Well-Being in Boys With Constitutional Delay of Puberty: A Randomized Controlled Trial.
Trial report in Clinical endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Puberty-Promoting Treatment and Psychosocial Well-Being in Boys With Constitutional Delay of Puberty: A Randomized Controlled Trial.Clinical endocrinology · 2026Trial
- Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence.Clinics and practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveIn boys, constitutional delay of growth and puberty (CDGP) has been associated with diverse negative psychosocial effects. Albeit alleviating distress is one of the main reasons for inducing pubertal development, the impact of puberty-promoting treatment on psychosocial wellbeing is under-researched. Our objective was to investigate the impact of puberty-promoting therapies on the behavioural patterns as defined by the temperament characteristics emotionality, activity, and sociability (EAS) in boys with CDGP.
designThe study is a randomized, controlled, open-label trial. PATIENTS: Thirty boys were randomized to receive either aromatase inhibitor letrozole (2.5 mg/day) (n = 15) or intramuscular testosterone (1 mg/kg/every 4 weeks) (n = 15) for 6 months and followed up to 12 months. To compare our results with healthy peers, an age- and postal-code matched, and a national reference population were collected. MEASUREMENTS: Temperament characteristics were evaluated with a standardized and validated questionnaire at 0-, 6-, and 12-month visits.
resultsIn comparison to local peers, boys with CDGP were more withdrawn (p = 0.02) and experienced less anger (p = 0.02) and fear (p = 0.02). Compared to both local and national controls, there was a significant difference in emotionality, CDGP boys being less negatively emotional than peers (p = 0.04). Sociability was higher in the Lz-group in comparison to the T-group both after the 6-month treatment period (-0.48, 95% CI: 0.89; -0.08, p = 0.019) and at 12-month follow-up (-0.72, CI: 95%, -1.12; -0.32, p = 0.001).
conclusionOverall, boys with CDGP exhibited a generally docile temperament. The administration of puberty-promoting treatments did not result in any adverse psychosocial effects on the temperament characteristics assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.